

**Professor David Denning** FRCP FRCPath FIDSA DCH FMedSci  
Professor of Medicine and Medical Mycology, University of Manchester  
Director, National Aspergillosis Centre, University Hospital of South Manchester (Wythenshawe)

David Denning is an infectious diseases clinician with expertise in fungal diseases, working in an academic respiratory medicine department in a University hospital. He manages the National Aspergillosis Centre, Manchester which is the referral centre in the UK for all patients with chronic pulmonary aspergillosis (a population of 61 million). His group undertakes basic research (genomics, pathogenesis and mechanism of antifungal drug resistance), applied laboratory work (antifungal resistance testing and validation in models, pharmacodynamics, models of pathogenesis, molecular diagnostics), and clinical studies (description of the natural history of fungal infection, human genetics of aspergillosis and therapy studies). His current foci of interest are chronic and allergic pulmonary fungal disease, fungal diagnostics and azole resistance in *Aspergillus*. He has published more than 400 papers, books and book chapters, including an undergraduate textbook of Medicine. His work has been cited over 18,000 times. He is the Founder of 2 University spinout biotechnology companies – F2G Ltd (antifungal drug discovery and development) and Myconostica Ltd (molecular diagnostic tests for fungi), now sold to Lab21. He is the managing Editor of The Aspergillus Website (1998-) with over 1 million pages read per month. He has chaired the Scientific Committees of several international fungal infection meetings, and co-chairs the alternate year Advances Against Aspergillosis meetings, attracting >500 delegates for >120 countries. Currently he is interested in exporting his knowledge through education globally and work in partnership with ISHAM to make a step-change in the field with respect to improving patient outcomes.